TORONTO, April 23, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused
SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing
Toronto, Ontario–(Newsfile Corp. – April 23, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland”), a company engaged in
Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB), is distinct from most germs in its capacity to silently infect individuals for months and even years
Share this article Hepion has “begun wind-down activities” for the programme as it assesses alternative strategies. Image credit: Shuttestock/Pasuwan. Hepion Pharmaceuticals has called it quits
Dry Eye Disease (DED) is one of the more common eye diseases, affecting up to 30% of the world’s population.
Every year, between 250,000 and 300,000 people in Germany suffer from a stroke or heart attack.
Day One Biopharmaceuticals said Tuesday the Food and Drug Administration gave accelerated approval to its targeted pill for one of the most common forms of
What You Should Know: – Cohere Health, a recognized leader in clinical intelligence and prior authorization automation, announced that Humana Inc. (NYSE: HUM) will expand its use of
What You Should Know: Exo® (pronounced “echo”), a medical imaging software and devices company, today announced its FDA-cleared cardiac and lung artificial intelligence (AI) applications